Sharma VK, et al. - In this retrospective review, researchers characterized the long-term safety and efficacy of rituximab in the treatment of pemphigus and compared the treatment results when rituximab is used as first-line treatment vis-à-vis after treatment failure or relapse. Participants in the study were 61 patients with pemphigus treated with rituximab. Serious adverse effects related to treatment have been observed in 6 patients. In the treatment of pemphigus, rituximab is a safe and effective adjuvant. Treatment results for patients receiving rituximab as first-line treatment were better, but the distinction was not statistically important.